The study will aim to evaluate the following:

• Whether there are any differences in the way the body handles LY2963016 U-200 and LY2963016 U-100.
• How well-tolerated LY2963016 U-200 is compared with LY2963016 U-100.
• How LY2963016 U-200 affects the level of blood sugar in the body compared with LY2963016 U-100.

The study will last up to 17 weeks for each participant, including initial screening and follow up.

Inclusion Criteria:

• Have a body mass index (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m²)
• Have a fasting plasma glucose less than (<) 6.0 millimoles per liter (mmol/L) (108 milligram per deciliter [mg/dL])
• Have venous access sufficient to allow for blood sampling and clamp procedures per protocol

Exclusion Criteria:

• Have known allergies to the study drug, or any components of the formulation
• Have donated or had a blood loss of 450 milliliter (mL) within 3 months prior to study enrollment